2.07
-0.06 (-2.80%)
| Previous Close | 2.13 |
| Open | 2.14 |
| Volume | 42,279 |
| Avg. Volume (3M) | 250,353 |
| Market Cap | 54,914,916 |
| Price / Sales | 255.50 |
| Price / Book | 6.21 |
| 52 Weeks Range | |
| Earnings Date | 24 Mar 2025 - 28 Mar 2025 |
| Diluted EPS (TTM) | -1.07 |
| Total Debt/Equity (MRQ) | 6.85% |
| Current Ratio (MRQ) | 2.84 |
| Operating Cash Flow (TTM) | -18.97 M |
| Levered Free Cash Flow (TTM) | -10.06 M |
| Return on Assets (TTM) | -72.96% |
| Return on Equity (TTM) | -188.83% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (US) | Mixed | Mixed |
| Biotechnology (Global) | Mixed | Mixed | |
| Stock | Gain Therapeutics, Inc. | Bearish | Bearish |
AIStockmoo Score
| Analyst Consensus | 3.0 |
| Insider Activity | NA |
| Price Volatility | -2.0 |
| Technical Moving Averages | 1.0 |
| Technical Oscillators | 0.5 |
| Average | 0.63 |
|
Gain Therapeutics Inc is a biotechnology company developing novel small molecule therapeutics to treat diseases across, several therapeutics areas, including, lysosomal storage disorders, central nervous system disorders, metabolic disorders, and oncology. The company's clinical-stage product candidate, GT-02287, is being developed for the treatment of GBA1 Parkinson’s disease. The company uses its computational target and drug discovery platform, Magellan, to discover novel allosteric binding sites on proteins implicated in disease and to identify proprietary small molecules that bind these sites to modulate protein function and treat the underlying cause of the disease. The company derives revenues from collaboration and licensing agreements. |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| Investment Style | Small Value |
| % Held by Insiders | 5.09% |
| % Held by Institutions | 7.96% |
Ownership
| Name | Date | Shares Held |
|---|---|---|
| Gotham Asset Management, Llc | 30 Sep 2024 | 334,592 |
| Sandhill Capital Partners Llc | 30 Sep 2024 | 15,400 |
| 52 Weeks Range | ||
| Price Target Range | ||
| High | 8.00 (HC Wainwright & Co., 286.42%) | Buy |
| Median | 7.50 (262.27%) | |
| Low | 7.00 (Roth MKM, 238.12%) | Buy |
| Average | 7.50 (262.27%) | |
| Total | 2 Buy | |
| Avg. Price @ Call | 1.71 | |
| Firm | Date | Target Price | Call | Price @ Call |
|---|---|---|---|---|
| Roth MKM | 24 Dec 2024 | 7.00 (238.12%) | Buy | 1.59 |
| 05 Dec 2024 | 7.00 (238.12%) | Buy | 1.71 | |
| HC Wainwright & Co. | 25 Nov 2024 | 8.00 (286.42%) | Buy | 1.82 |
No data within this time range.
| Date | Type | Details |
|---|---|---|
| 08 Jan 2025 | Announcement | Gain Therapeutics Announces Formation of Clinical Advisory Board to Support Continued Advancement of Lead Drug Candidate GT-02287 |
| 07 Jan 2025 | Announcement | Gain Therapeutics Appoints Gene Mack as Chief Executive Officer and Director |
| 23 Dec 2024 | Announcement | Gain Therapeutics Initiates Phase 1b Clinical Trial of Lead Candidate GT-02287 in People with GBA1 and Idiopathic Parkinson’s Disease |
| 11 Dec 2024 | Announcement | Gain Therapeutics To Present At Biotech Showcase 2025 |
| 14 Nov 2024 | Announcement | Gain Therapeutics Reports Financial Results for Third Quarter 2024 and Provides Corporate Update |
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2025 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |